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BRIEF REPORT: CLINICAL SCIENCE
Cobicistat Compared With Ritonavir as
a Pharmacoenhancer for Atazanavir in Combination With
Emtricitabine/Tenofovir Disoproxil Fumarate:
Week 144 Results
Joel E. Gallant, MD, MPH,* Ellen Koenig, MD,† Jaime F. Andrade-Villanueva, MD,‡
Ploenchan Chetchotisakd, MD,§ Edwin DeJesus, MD,k Francisco Antunes, MD, PhD,¶
Keikawus Arastéh, MD,# Giuliano Rizzardini, MD,** Jan Fehr, MD,†† Hui C. Liu, PhD,‡‡
Michael E. Abram, PhD,‡‡ Huyen Cao, MD,‡‡ and Javier Szwarcberg, MD‡‡
Background: Cobicistat (COBI) is a pharmacoenhancer with no
antiretroviral activity.
Methods: International, randomized double-blind active-controlled
trial to evaluate the efﬁcacy and safety of COBI vs ritonavir (RTV)
as a pharmacoenhancer of atazanavir in combination with emtrici-
tabine/tenofovir disoproxil fumarate in HIV treatment-naive patients
followed through week 144.
Results: At Week 144, virologic suppression was achieved in 72%
(COBI) and 74% (RTV) of patients. Adverse events leading to study
drug discontinuation occurred in 11% of patients in each group.
Median changes in serum creatinine (mg/dL) were +0.13 (COBI)
and +0.07 (RTV) and were unchanged from week 48.
Conclusions: Once-daily COBI is a safe and effective pharma-
coenhancer of the protease inhibitor atazanavir.
Key Words: Cobicistat, pharmacoenhancer, HIV, Antiretroviral,
clinical trial
(J Acquir Immune Deﬁc Syndr 2015;69:338–340)
INTRODUCTION
Cobicistat (COBI) is a pharmacoenhancer of protease
inhibitors (PIs) or elvitegravir (EVG). COBI has a lower
potential for off-target drug interactions than the standard
boosting agent ritonavir (RTV), because of its more selective
inhibition of cytochrome CYP3A and lower likelihood for
enzymatic induction.1,2 Unlike RTV, it has no anti-HIV
activity. The 144-week safety and efﬁcacy of the single-
tablet regimen of EVG/COBI/emtricitabine/tenofovir disoprox-
il fumarate (FTC/TDF) has been previously demonstrated.3
The safety and efﬁcacy of COBI vs RTV as a pharma-
coenhancer for atazanavir (ATV) in combination with FTC
and TDF was evaluated in a randomized phase 3 trial (study
GS-216-114). Week 48 clinical data demonstrated that COBI
was safe, well-tolerated, and noninferior to RTV.3 Here, we
present the week 144 safety and efﬁcacy data from study GS-
US-216-0114 (clinical trials registration NCT01108510).
METHODS
A full description of the methods has been published.4
Brieﬂy, this international phase 3 double-blind and double-
dummy study was approved by institutional review board at
all investigative centers. Participants were HIV-1–infected
adults with plasma HIV-1 RNA $5000 copies per milliliter
and no previous use of antiretroviral agents. Key inclusion
criteria included an estimated glomerular ﬁltration rate
(eGFR) of at least 70 mL/min and genotypic sensitivity to
ATV, FTC, and TDF at screening. Eligible patients were
randomized 1:1 to receive either COBI or RTV and matching
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placebo, each administered once daily with ATV plus FTC/
TDF. After week 48, study visits occurred every 12 weeks
until week 144. In patients taking study drugs with conﬁrmed
virologic rebound of HIV-1 RNA $400 copies per milliliter,
genotype and phenotype assays were performed on the
conﬁrmatory sample (Monogram Biosciences, South San
Francisco, CA). Efﬁcacy was determined as the proportion
of patients with virologic suppression (HIV-1 RNA ,50
copies/mL) at week 144 using the US Food and Drug
administration–deﬁned snapshot analysis.
RESULTS
A total of 692 patients were randomized and treated:
344 in the COBI group and 348 in the RTV group.
Demographic and general baseline characteristics, and safety
and efﬁcacy through week 48 have been reported previously.4
Virologic responses in the COBI group were compara-
ble with the RTV group (COBI, 72.1%; RTV, 74.1%) at week
144 (Fig. 1). Mean increases in CD4 cell count at week 144
were similar in the 2 groups (+310 and +332 cells per mL).
Development of resistance to the study regimens was
infrequent through week 144; 3 patients in the COBI group
and 1 in the RTV group developed resistance to FTC. No
patients developed resistance to either PI or TDF.
The overall safety ﬁndings through week 144 were
consistent with those through week 48. Similar percentages of
patients in each group reported an adverse event (AE) (COBI,
96.5% and RTV, 95.7%). The most commonly reported AEs
in the COBI group were diarrhea (22.4%), jaundice (21.8%),
and scleral icterus (19.8%), and in RTV group were diarrhea
(27.6%), scleral icterus (21.8%), and nasopharyngitis (20.7%)
(Table 1). The most common AEs related to the study drug
were due to elevated bilirubin, which occurred in a similar
percentage of patients in the COBI and RTV groups (43.6%
vs 41.4%); these were also the most common AEs leading to
discontinuation in both groups (4.9% vs 4.0%). Rates of
diarrhea and nausea were similar between the 2 groups. The
percentage of patients with serious AEs considered related to
the study drug (COBI, 1.7%; RTV, 2.9%), or who discon-
tinued the study drug because of an AE (COBI, 11.0%; RTV,
11.2%) was similar between the 2 treatment arms.
At week 144, a small increase in serum creatinine
(median change from baseline +0.13 vs +0.07 mg/dL) and
a corresponding decrease in eGFR (median change 215.1 vs
27.5 mL/min) were observed in both groups. These changes
occurred by week 4 with little progression between weeks 48
and 144 (P . 0.05), consistent with results from studies of
EVG/COBI/FTC/TDF and because of inhibition of tubular
creatinine secretion. Seven patients (2.0%) in each group
developed proximal renal tubulopathy (PRT). In 5 of the 7
patients in the COBI group and 6 of the 7 patients in the RTV
group, PRT occurred after week 48. In the COBI-containing
regimen, reversibility of renal laboratory abnormalities was
seen in 6 of the 7 patients after discontinuation of the study
drug (1 patient did not discontinue the study drug). Of those 6
patients, renal laboratories normalized or returned to baseline
in 3; among the other 3 subjects with persistent laboratory
abnormalities after discontinuation, 2 patients did not have
a sufﬁciently long follow-up period to assess full reversibility
and 1 patient started RTV boosted ATV + FTC/TDF.
There were no signiﬁcant differences between treatment
groups from baseline to week 144 in median increase in
fasting total cholesterol (+12 vs +16 mg/dL), LDL cholesterol
(+9 vs +14 mg/dL), HDL cholesterol (+7 vs +5 mg/dL), or
triglycerides (+11 vs +15 mg/dL). Median changes in total
cholesterol to HDL cholesterol ratio were also similar (20.3
vs 20.2).
FIGURE 1. Patients achieving virologic success (HIV-1 RNA
,50 copies/mL) through weeks 48 and 144. *No data include
discontinuation and the last available HIV-1 RNA ,50 copies/
mL or missing data during window.
TABLE 1. Adverse Events
COBI
(n = 344)
RTV
(n = 348)
W48 W144 W48 W144
AE (% reported in $10% of
patients in either group)
Jaundice 20.9 21.8 15.5 17.2
Scleral icterus 17.7 19.8 18.4 21.8
Nausea 17.7 19.2 16.4 19.0
Diarrhea 15.4 22.4 20.4 27.6
Hyperbilirubinemia 11.3 12.2 9.8 11.2
Headache 11.0 14.5 15.5 20.1
Nasopharyngitis 10.8 15.4 15.2 20.7
URTI 10.2 16.6 8.0 17.8
Fatigue 7.6 10.2 6.9 9.8
Fever 5.5 10.2 7.2 8.9
Back pain 4.7 8.7 6.9 11.2
AE leading to study discontinuation
(.1 patient in either group)
Scleral icterus 2.3 3.5 1.1 1.4
Jaundice 2.6 2.9 2.0 2.0
Hyperbilirubinemia 0.3 0.3 0.6 0.9
Renal abnormalities (proximal
tubulopathy)
1.7
(1.5)
2.9
(1.7)
1.4
(0.6)
3.2
(0.6)
Rash 0.3 0.3 0.6 0.6
Allergic dermatitis 0.6 0.6 0 0
Data are % of patients.
URTI, upper respiratory tract infection.
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DISCUSSION
In this randomized double-blinded study, COBI demon-
strated persistent and comparable efﬁcacy relative with RTV as
a pharmacoenhancer of ATV at week 144. No new safety
concerns emerged at week 144. AEs, including bilirubin
elevations, jaundice, nausea, and diarrhea, and study drug
discontinuations because of AEs were similar in both groups.
Both COBI and RTV inhibit the tubular secretion of
creatinine, with no effect on actual GFR.5–8 Consistent with
these ﬁndings, a small increase in serum creatinine was seen
in both COBI and RTV groups in our study, with COBI
having the greater effect. The rates of renal discontinuation in
our study were similar to previous studies of TDF-containing
boosted PI regimen ranging from 0% to 3%.9–17 In our study,
a small and similar number of patients discontinued the study
drug because of PRT [COBI, n = 6 (1.7%) and RTV, n = 7
(2.0%)]. This is consistent with the safety proﬁle of TDF,
which has been associated with PRT.18 In all patients in the
COBI group who developed PRT and had follow-up data,
tubular abnormalities (proteinuria, glycosuria, or hypophos-
phatemia) reversed and serum creatinine improved after
discontinuation of study medication.
COBI is a mechanism-based inhibitor of cytochrome
P450 3A enzymes that is used as pharmacoenhancer of PIs or
EVG. The chemical properties of COBI allow for coformulation
with other antiretroviral agents such as ﬁxed-dose combination
tablets containing EVG, ATV, and darunavir. COBI provides
an alternative to RTV as a pharmacoenhancer for antiretroviral
therapy containing a PI in adults with HIV-1 infection.
REFERENCES
1. Xu L, Liu H, Murray BP, et al. Cobicistat (GS-9350): a potent and
selective inhibitor of human CYP3A as a novel pharmacoenhancer. ACS
Med Chem Lett. 2010;1:209–213.
2. Mathias AA, German P, Murray BP, et al. Pharmacokinetics and
pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer
without anti-HIV activity. Clin Pharmacol Ther. 2010;87:322–329.
3. Clumeck N, Molina JM, Henry K, et al. A randomized, double-blind
comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabi-
ne/tenofovir DF vs ritonavir-boosted atazanavir plus emtricitabine/teno-
fovir DF for initial treatment of HIV-1 infection: analysis of week 144
results. J Acquir Immune Deﬁc Syndr. 2014;65:e121–124.
4. Gallant JE, Koenig E, Andrade-Villanueva J, et al. Cobicistat versus
ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/teno-
fovir disoproxil fumarate in treatment-naive HIV type 1-infected patients:
week 48 results. J Infect Dis. 2013;208:32–39.
5. Cohen C, Elion R, Ruane P, et al. Randomized, phase 2 evaluation of two
single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir
disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil
fumarate for the initial treatment of HIV infection. AIDS. 2011;25:
F7–F12.
6. Elion R, Cohen C, Gathe J, et al. Phase 2 study of cobicistat versus
ritonavir each with once-daily atazanavir and ﬁxed-dose emtricitabine/-
tenofovir df in the initial treatment of HIV infection. AIDS. 2011;25:
1881–1886.
7. German P, Liu HC, Szwarcberg J, et al. Effect of cobicistat on glomerular
ﬁltration rate in subjects with normal and impaired renal function. J
Acquir Immune Deﬁc Syndr. 2012;61:32–40.
8. Lepist EI, Zhang X, Hao J, et al. Contribution of the organic anion
transporter OAT2 to the renal active tubular secretion of creatinine and
mechanism for serum creatinine elevations caused by cobicistat. Kidney
Int. 2014;86:350–357.
9. Elion R, Cohen C, Ward D, et al. Evaluation of efﬁcacy, safety,
pharmacokinetics, and adherence in HIV-1-infected, antiretroviral-naive
patients treated with ritonavir-boosted atazanavir plus ﬁxed-dose teno-
fovir DF/emtricitabine given once daily. HIV Clin Trials. 2008;9:
213–224.
10. Smith KY, Patel P, Fine D, et al. Randomized, double-blind, placebo-
matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricita-
bine with lopinavir/ritonavir for initial HIV treatment. AIDS. 2009;23:
1547–1556.
11. Mills AM, Nelson M, Jayaweera D, et al. Once-daily darunavir/ritonavir
vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-
week analysis. AIDS. 2009;23:1679–1688.
12. Johnson MA, Gathe JC Jr, Podzamczer D, et al. A once-daily
lopinavir/ritonavir-based regimen provides noninferior antiviral activity
compared with a twice-daily regimen. J Acquir Immune Deﬁc Syndr.
2006;43:153–160.
13. Walmsley S, Avihingsanon A, Slim J, et al. Gemini: a noninferiority
study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-1
therapy in adults. J Acquir Immune Deﬁc Syndr. 2009;50:367–374.
14. Soriano V, Arasteh K, Migrone H, et al. Nevirapine versus atazanavir/-
ritonavir, each combined with tenofovir disoproxil fumarate/emtricita-
bine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial. Antivir
Ther. 2011;16:339–348.
15. McGrath D, Zhu L, Thiry A, et al. Renal function in treatment-naïve
subjects exposed to tenofovir/emtricitabine in combination with ataza-
navir/ritonavir or lopinavir/ritonavir: 48-week results from the CASTLE
study (BMS AI424138) [THPE0190]. Presented at: 17th International
AIDS Conference; August 3, 2008; Mexico City, Mexico.
16. da Silva B, Cohen D, Gibbs S, et al. Renal function in treatment-naïve
subjects exposed to tenofovir/emtricitabine in combination with ataza-
navir/ritonavir or lopinavir/ritonavir: 48-week results from the CASTLE
study (BMS AI424138). In: Program and Abstracts of the 10th
International Workshop on Adverse Drug Reactions and Lipodystrophy
in HIV (London, UK). London, UK: International Medical Press, 2008.
17. Smith KY, Weinberg WG, Dejesus E, et al. Fosamprenavir or atazanavir
once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine,
for the initial treatment of HIV infection: 48-week results of ALERT.
AIDS Res Ther. 2008;5:5.
18. Gilead Sciences. Viread (tenofovir disoproxil fumarate) US prescribing
information. Available at: http://www.gilead.com/pdf/viread_pi.pdf. Ac-
cessed November 1, 2010.
Gallant et al J Acquir Immune Defic Syndr  Volume 69, Number 3, July 1, 2015
340 | www.jaids.com Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
Copyright © 201 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.5
